Translate Bio Inc

NASDAQ:TBIO   3:59:56 PM EDT
23.00
-0.33 (-1.41%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.68B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$17.14 Million
Adjusted EPS-$0.34
See more estimates
10-Day MA$22.39
50-Day MA$20.74
200-Day MA$16.58
See more pivots

Translate Bio, Inc. Stock, NASDAQ:TBIO

29 HARTWELL AVENUE, LEXINGTON, MA 02421
United States of America
Phone: 617-945-7361
Number of Employees: 81

Description

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious disease pathogens, as well as against COVID-19. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.